Skip to main content
The Globe and Mail
Support Quality Journalism.
The Globe and Mail
First Access to Latest
Investment News
Collection of curated
e-books and guides
Inform your decisions via
Globe Investor Tools
Just$1.99
per week
for first 24 weeks

Enjoy unlimited digital access
Enjoy Unlimited Digital Access
Get full access to globeandmail.com
Just $1.99per week for the first 24weeks
Just $1.99per week for the first 24weeks
var select={root:".js-sub-pencil",control:".js-sub-pencil-control",open:"o-sub-pencil--open",closed:"o-sub-pencil--closed"},dom={},allowExpand=!0;function pencilInit(o){var e=arguments.length>1&&void 0!==arguments[1]&&arguments[1];select.root=o,dom.root=document.querySelector(select.root),dom.root&&(dom.control=document.querySelector(select.control),dom.control.addEventListener("click",onToggleClicked),setPanelState(e),window.addEventListener("scroll",onWindowScroll),dom.root.removeAttribute("hidden"))}function isPanelOpen(){return dom.root.classList.contains(select.open)}function setPanelState(o){dom.root.classList[o?"add":"remove"](select.open),dom.root.classList[o?"remove":"add"](select.closed),dom.control.setAttribute("aria-expanded",o)}function onToggleClicked(){var l=!isPanelOpen();setPanelState(l)}function onWindowScroll(){window.requestAnimationFrame(function() {var l=isPanelOpen(),n=0===(document.body.scrollTop||document.documentElement.scrollTop);n||l||!allowExpand?n&&l&&(allowExpand=!0,setPanelState(!1)):(allowExpand=!1,setPanelState(!0))});}pencilInit(".js-sub-pencil",!1); // via darwin-bg var slideIndex = 0; carousel(); function carousel() { var i; var x = document.getElementsByClassName("subs_valueprop"); for (i = 0; i < x.length; i++) { x[i].style.display = "none"; } slideIndex++; if (slideIndex> x.length) { slideIndex = 1; } x[slideIndex - 1].style.display = "block"; setTimeout(carousel, 2500); } //

Bausch Health reported quarterly results on Tuesday.

Ryan Remiorz/The Canadian Press

Bausch Health Companies Inc. is preparing to spin off its eyecare business this fall while also considering suitable alternatives including a sale of the business, the company’s CEO said Tuesday.

“We have a value in our mind for that business. But if there are others that want to pay a price that is equivalent to that value, we’re always going to do what we believe is the right thing to do for our shareholders and evaluate that those types of offers,” chairman and CEO Joseph Papa told analysts during a conference call about Bausch Health’s first quarter report.

He added that the company has a pathway to spin off Bausch and Lomb sometime after October but will always be open to other alternatives or pathways that create value for shareholders.

Story continues below advertisement

The Quebec-based company announced that Papa will head the new eyecare business while Sam Eldessouky will become chief financial officer with Paul Herendeen’s departure from the role on May 31 to become special adviser to the chairman.

A new leadership team will be selected in the coming couple of months to run the remaining part of the business, referred to as Bausch Pharma until it is rebranded.

Both companies will remain domiciled in Canada and will have corporate offices in Bridgewater, N.J. It also plans to apply to list Bausch and Lomb on the Toronto and New York stock exchanges, where the overall company is currently listed.

“We believe that both B&L and Bausch Pharma have the ability to grow revenue organically in the mid-single digits for a number of years,” Herendeen said.

“Looking ahead, our process remains on execution, growth and positioning these two strong but dissimilar businesses for attractive growth and opportunities in the markets they serve.”

Bausch reported a first-quarter loss of US$610 million compared with a loss of US$152 million a year earlier.

The company, which keeps its books in U.S. dollars, says the loss amounted to US$1.71 per diluted share for the quarter compared with a loss of 43 cents per diluted share in the first three months of 2020.

Story continues below advertisement

The results included a US$469-million goodwill impairment charge in its Ortho Dermatologics business and a US$71-million impairment charge related to a product line in Ortho Dermatologics.

On an adjusted basis, Bausch Health says it earned US$370 million for the quarter, up from an adjusted profit of US$316 million for same quarter last year.

Revenue for the quarter totalled nearly US$2.03 billion compared with US$2.01 billion in the first quarter of 2020. It sustained a negative impact from COVID-19 of about US$100 million.

“Overall, our team has been able to adapt to the pandemic related challenges and despite a few pockets of variability, recovery is in progress across our business,” Papa said.

The eyecare business accounted to 44 per cent of overall revenues of US$881 million, up from US$875 million a year ago.

The company was expected to report an adjusted profit of US$337.9 million on US$2.06 billion of revenues, according the financial data firm Refinitiv.

Story continues below advertisement

Bausch Health says excluding the US$33-million favourable impact of foreign exchange and the $10-million impact of divestitures and discontinuations, revenue fell US$8 million compared with a year ago.

“We entered 2021 with strong momentum, and our first quarter results demonstrate that the recovery is in progress. Our business is generating strong cash flows, and our leading products are poised for growth in key markets,” added Papa.

The spinoff eyecare business is expected to have net leverage of less than 2.5 times capital invested while the remaining pharma business will have a targeted 6.5 to 6.7 times.

Moody’s Investors Service said the target for Bausch Pharma resulting from the spinoff of eyecare is “credit negative for the remaining business” compared to the previous target of 5.5 times.

“Previously, Moody’s envisioned that a spinoff represented a more substantial deleveraging opportunity for the remaining business,” it said in a news release.

Meanwhile, Douglas Miehm of RBC Dominion Securities called Bausch Health’s overall first-quarter results were “relatively neutral.”

Story continues below advertisement

On the Toronto Stock Exchange, Bausch’s shares lost $4.21 or 10.9 per cent at $34.38 in afternoon trading.

Your time is valuable. Have the Top Business Headlines newsletter conveniently delivered to your inbox in the morning or evening. Sign up today.

Your Globe

Build your personal news feed

  1. Follow topics and authors relevant to your reading interests.
  2. Check your Following feed daily, and never miss an article. Access your Following feed from your account menu at the top right corner of every page.

Follow topics related to this article:

View more suggestions in Following Read more about following topics and authors
Report an error
Tickers mentioned in this story
Due to technical reasons, we have temporarily removed commenting from our articles. We hope to have this fixed soon. Thank you for your patience. If you are looking to give feedback on our new site, please send it along to feedback@globeandmail.com. If you want to write a letter to the editor, please forward to letters@globeandmail.com.

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff.

We aim to create a safe and valuable space for discussion and debate. That means:

  • Treat others as you wish to be treated
  • Criticize ideas, not people
  • Stay on topic
  • Avoid the use of toxic and offensive language
  • Flag bad behaviour

If you do not see your comment posted immediately, it is being reviewed by the moderation team and may appear shortly, generally within an hour.

We aim to have all comments reviewed in a timely manner.

Comments that violate our community guidelines will not be posted.

UPDATED: Read our community guidelines here

Discussion loading ...

To view this site properly, enable cookies in your browser. Read our privacy policy to learn more.
How to enable cookies